Drugs / Insulin aspart30
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07387003 Comparator | Apr 2026 → Feb 2027 expected | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03700801 Comparator | Oct 2018 → Dec 2019 | type 2 diabetes mellitus | Zhujiang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01293396 Comparator | Jun 2010 → Feb 2011 | type 2 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Aspart 30 | “Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM” NCT03700801 ↗ |
| Known as | NovoRapid30 | “GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)” NCT07387003 ↗ |
| Route | Subcutaneous | “Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM” NCT03700801 ↗ |